Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Nov;27(11):942-960.
doi: 10.1111/tmi.13819. Epub 2022 Oct 18.

Availability and affordability of essential medicines and diagnostic tests for diabetes mellitus in Africa

Davis Kibirige  1   2 , Ronald Olum  3   4 , Andrew Peter Kyazze  5 , Felix Bongomin  4   6 , Richard E Sanya  7
Affiliations
Free article
Meta-Analysis

Availability and affordability of essential medicines and diagnostic tests for diabetes mellitus in Africa

Davis Kibirige et al. Trop Med Int Health. 2022 Nov.
Free article

Abstract

Objective: To investigate the current status of the availability and affordability of specific essential medicines and diagnostics for diabetes in Africa.

Methods: Systematic review and meta-analysis. Studies conducted in Africa that reported any information on the availability and affordability of short-acting, intermediate-acting, and premixed insulin, glibenclamide, metformin, blood glucose, glycated haemoglobin or HbA1c, and lipid profile tests were included. Random-effect model meta-analysis and descriptive statistics were performed to determine the pooled availability and affordability, respectively.

Results: A total of 21 studies were included. The pooled availability of each drug was as follows: short-acting insulin 33.5% (95% CI: 17.8%-49.2%, I2 = 95.02%), intermediate-acting insulin 23.1% (95% CI: 6.3%-39.9%, I2 = 91.6%), premixed insulin 49.4% (95% CI: 24.9%-73.9%, I2 = 90.57%), glibenclamide 55.9% (95% CI: 43.8%-68.0%, I2 = 96.7%), and metformin 47.0% (95% CI: 34.6%-59.4%, I2 = 97.54%). Regarding diagnostic tests, for glucometers the pooled availability was 49.5% (95% CI: 37.9%-61.1%, I2 = 97.43%), for HbA1c 24.6% (95% CI: 3.1%-46.1%, I2 = 91.64), and for lipid profile tests 35.7% (95% CI: 19.4%-51.9%, I2 = 83.77%). The median (IQR) affordability in days' wages was 7 (4.7-7.5) for short-acting insulin, 4.4 (3.9-4.9) for intermediate-acting insulin, 7.1 (5.8-16.7) for premixed insulin, 0.7 (0.7-0.7) for glibenclamide, and 2.1 (1.8-2.8) for metformin.

Conclusion: The availability of the five essential medicines and three diagnostic tests for diabetes in Africa is suboptimal. The relatively high cost of insulin, HbA1c, and lipid profile tests is a significant barrier to optimal diabetes care. Pragmatic country-specific strategies are urgently needed to address these inequities in access and cost.

Keywords: Africa; affordability; availability; diabetes mellitus; diagnostic tests; essential medicines.

PubMed Disclaimer

References

REFERENCES

    1. IDF. International diabetes federation diabetes atlas. https://diabetesatlasorg (2021). Accessed 12 Nov 2021.
    1. Atun R, Davies JI, Gale EAM, Bärnighausen T, Beran D, Kengne AP, et al. Diabetes in sub-Saharan Africa: from clinical care to health policy. Lancet Diabetes Endocrinol. 2017;5(8):622-67.
    1. UN General Assembly. Political declaration of the high-level meeting of the general assembly on the prevention and control of non-communicable diseases. http://wwwwhoint/nmh/events/un_ncd_summit2011/political_declaration_enpdf. Accessed 2 May 2018.
    1. WHO. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. http://appswhoint/medicinedocs/en/d/Js21446en/ (2013). Accessed 2 May 2018.
    1. WHO. World Health Organization. Package of Essential Non-communicable (PEN) Disease Interventions for Primary Health Care in Low-Resource Settings. http://whqlibdoc.who.int/publications/2010/9789241598996_eng (2010). Accessed 25 Jul 2019.

LinkOut - more resources